Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 6/20 | 0.48 |
| ▸ | PTPRC | P08575 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.37 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.37 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.37 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.34 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21774240 | 0.85 | ERN1 (0.49) | ERN1PTPRCCYP2A6CYP2B6CYP2E1 | |
| SCHEMBL609426 | 0.82 | ERN1 (0.49) | ERN1PTPRCCYP2A6CYP2B6CYP2E1 | |
| SCHEMBL7533951 | 0.80 | ERN1 (0.51) | ERN1PTPRCCYP2A6CYP2B6CYP2E1 | |
| SCHEMBL16399564 | 0.78 | LMNA (0.48) | ERN1MEN1LMNATHRBBLM | |
| SCHEMBL6438260 | 0.77 | PDGFRB (0.45) | ERN1PTPRCCYP2A6CYP2B6CYP2E1 | |
| SCHEMBL2359029 | 0.77 | ERN1 (0.44) | ERN1MEN1LMNATHRBBLM | |
| SCHEMBL13388033 | 0.77 | ERN1 (0.44) | ERN1PTPRCCYP2A6CYP2B6CYP2E1 | |
| SCHEMBL7528504 | 0.76 | CA1 (0.49) | ERN1MAOB | |
| SCHEMBL28918738 | 0.75 | ERN1 (0.49) | ERN1PTPRCCYP2A6CYP2B6CYP2E1 | |
| SCHEMBL15742298 | 0.74 | ERN1 (0.48) | ERN1MEN1LMNATHRBBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
| EP-1187824-B1 | NOVEL (2-SUBSTITUTED-5 - 3-THIENYL) -BENZYL]- 2- ( 2-ISOPROPOXY-5-FLUORO] -PHENOXY) -ETHYL] -AMINE DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | PF MEDICAMENT (FR) | 2002-11-13 | — | — | EP | disclosed |
| US-6417222-B1 | DRUGS FOR PSYCHOLOGICAL DISORDERS OR COGNITION ACTIVATORS | PIERRE FABRE MEDICAMENT (FR) | 2002-07-09 | — | — | US | disclosed |
| EP-1187824-A2 | NOVEL (2-SUBSTITUTED-5 - 3-THIENYL) -BENZYL]- 2- ( 2-ISOPROPOXY-5-FLUORO] -PHENOXY) -ETHYL] -AMINE DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | PIERRE FABRE MEDICAMENT (FR) | 2002-03-20 | — | — | EP | disclosed |
| WO-2000058282-A2 | NOVEL [(2-SUBSTITUTED-5 -[3-THIENYL) -BENZYL]-[2- ([2-ISOPROPOXY-5-FLUORO] -PHENOXY) -ETHYL] -AMINE DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | PIERRE FABRE MEDICAMENT (FR) | 2000-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | CS, PC, ACAT1 | ERN1 1852/4885PTPRC 1885/4885CYP2A6 3084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.